title: AURKA suppression induces DU145 apoptosis and sensitizes DU145 to docetaxel treatment.
abstract: The palliative therapy effect by docetaxel for CRPC patients makes it urgent to improve the therapy. It was suggested that PI3K and androgen receptor-directed combination therapy may be effective for prostate cancer (PCa) patients PTEN negative. However, for those patients PTEN positive, the mechanism of anti-apoptosis survival of cancer cells is not yet well defined. Amplification of AURKA has been detected in 5% of PCa. In this work, Du145, a PTEN positive PCa cell model, was employed to investigate the role of aurora kinase a (AURKA) on cell growth. Inhibition of AURKA expression by shRNA markedly reduced prostate cancer cell viability. Furthermore, we demonstrate that AURKA inhibition induced a remarkable downregulation of AKT activity and Bax induction. Moreover, specific inhibition of the activity of AURKA, but not other aurora family members, by small molecular chemical inhibitors induced significant cell killing effects. Notably, AURKA inhibition sensitized prostate cancer cells to docetaxel treatment. Our work suggests that AURKA-directed monotherapy or combination therapy with docetaxel could be a potent treatment for PCa patients in future.
authors: Department of Urology, Ruijin hospital, Shanghai Jiaotong University, school of medicine Shanghai, China.
authors: Wei
authors: W
authors: He
authors: Min-Guang
authors: MG
authors: Zhang
authors: Xiao-Jing
authors: XJ
authors: Wang
authors: Shan
authors: S
authors: Zhong
authors: Yuan
authors: Y
authors: Shao
authors: Yu
authors: Y
authors: Zhu
authors: Zhou-Jun
authors: ZJ
authors: Shen
keywords: AURKA; Prostate cancer; aurora kinases; castration-resistant prostate cancer; docetaxel; p53
references: Oncogene. 2009 Feb 12;28(6):866-75
references: 19060929
references: Cancer Cell. 2009 Jan 6;15(1):67-78
references: 19111882
references: Gene Ther. 2010 Mar;17(3):352-9
references: 19956271
references: Leukemia. 2011 Feb;25(2):348-58
references: 21052088
references: Clin Cancer Res. 2008 Mar 15;14(6):1639-48
references: 18347165
references: Curr Treat Options Oncol. 2002 Oct;3(5):437-46
references: 12194808
references: Cancer Cell. 2011 May 17;19(5):575-86
references: 21575859
references: Cancer Res. 2010 Dec 1;70(23):9846-54
references: 20935223
references: Cancer Lett. 2008 Jan 18;259(1):28-38
references: 17977648
references: Nat Rev Drug Discov. 2007 Jul;6(7):556-68
references: 17599085
references: Cancer Res. 2008 Nov 1;68(21):8998-9004
references: 18974145
references: Radiat Res. 2011 Apr;175(4):444-51
references: 21222513
references: Cell Stem Cell. 2012 Aug 3;11(2):179-94
references: 22862944
references: FEBS Lett. 2011 Jun 23;585(12):1884-90
references: 21557940
references: Cancer Lett. 2010 Jul 1;293(1):1-14
references: 20117879
references: J Med Chem. 2009 May 28;52(10):3300-7
references: 19402633
references: Mol Cancer Ther. 2012 Mar;11(3):763-74
references: 22302096
references: Head Neck. 2009 May;31(5):625-34
references: 19107951
references: J Mol Med (Berl). 2013 Feb;91(2):237-48
references: 22945237
references: Free Radic Biol Med. 2011 May 1;50(9):1151-62
references: 21256211
references: Invest New Drugs. 2011 Oct;29(5):953-62
references: 20182906
references: J Natl Cancer Inst. 2008 Oct 1;100(19):1401-11
references: 18812553
references: Nat Methods. 2006 Oct;3(10):777-9
references: 16990807
references: BJU Int. 2013 Jan;111(1):44-52
references: 22928785
references: Mol Cell Biochem. 2011 Nov;357(1-2):95-106
references: 21590355
references: Cancer. 2008 Apr 15;112(8):1688-98
references: 18311783
references: N Engl J Med. 2004 Oct 7;351(15):1513-20
references: 15470214
references: Nature. 2008 Sep 4;455(7209):119-23
references: 18615013
references: Cancer Discov. 2011 Nov;1(6):487-95
references: 22389870
references: Cancer Res. 2005 Apr 1;65(7):2899-905
references: 15805292
references: Cancer Cell. 2011 Jun 14;19(6):792-804
references: 21620777
references: J Biol Chem. 2004 May 7;279(19):19643-8
references: 14990569
references: Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7131-6
references: 19359472
references: Prostate. 2006 Sep 15;66(13):1455-62
references: 16741917
references: Cancer Res. 1999 Sep 1;59(17):4291-6
references: 10485474
references: Leukemia. 2013 Mar;27(3):560-8
references: 22940834
references: Oncogene. 2008 Jul 3;27(29):4122-7
references: 18345035
references: Nat Rev Cancer. 2005 Jan;5(1):42-50
references: 15630414
references: Cancer Cell. 2009 Jan 6;15(1):5-6
references: 19111875
references: Nat Rev Cancer. 2010 Dec;10(12):825-41
references: 21102634
references: Cell Death Differ. 2012 Dec;19(12):1992-2002
references: 22790872
references: Mol Oncol. 2013 Jun;7(3):484-96
references: 23333597